Vitamin A / retinol
A nutritional substrate enters tissue-specific processing pathways.
Our science
Inhibiting nuclear receptor signaling upstream
Kayothera is pioneering first-in-class antagonists of the retinoid nuclear receptor pathway by targeting the formation of retinoid and rexinoid ligands.
Why this pathway matters
A historically difficult pathway with broad disease relevance
Kayothera is pioneering the development of safe, oral, first-in-class antagonists of the retinoid nuclear receptor pathway.
Activation of the retinoid pathway causes acute metabolic dysregulation and has a cancer-promoting effect in humans. The existing scientific rationale suggests retinoid nuclear receptor inhibitors may reverse progression across multiple cardiometabolic diseases and aggressive cancers.
Blocking the retinoid pathway has posed challenges to drug development for nearly three decades. Kayothera’s approach is designed to prevent formation of the retinoid nuclear receptor ligand upstream, analogous to how aromatase inhibitors prevent ligand formation in the Estrogen Receptor pathway.
Pathway overview
Vitamin A biology branches into powerful signaling pathways
Retinoid and rexinoid ligands activate RAR and RXR nuclear receptors, connecting upstream vitamin A biology with downstream transcriptional signaling.
Kayothera is focused on the enzymes and tissue-specific biology involved before receptor activation begins.
Retinoid ligand formation
ALDH1a enzymes participate in forming ligands that activate RAR nuclear receptors.
Rexinoid ligand formation
Related upstream biology supports ligands that activate RXR nuclear receptors.
RAR activation
Ligand-dependent RAR signaling influences transcriptional programs.
RXR activation
RXR signaling connects with metabolism, differentiation, and other pathway biology.
Downstream transcription
Nuclear receptor activation shapes tissue-specific biological responses.
Why inhibition matters
From pathway activation to pathway inhibition
A strategy shift toward controlling ligand formation upstream creates a shared scientific rationale across distinct tissue biology.
The pathway challenge
Retinoid and rexinoid signaling have long been studied through activation, while pathway inhibition remains an emerging therapeutic strategy.
Upstream ligand formation
Kayothera is designing small molecules to target ligand formation before RAR or RXR nuclear receptor activation.
Multi-disease rationale
The scientific foundation connects pathway biology with metabolism, cancer biology, and reproductive health.
Scientific mechanism
A new way to block disease-driving nuclear receptor signaling
Follow the pathway from vitamin A input through ligand-dependent transcriptional signaling, then see where Kayothera is designed to intervene.
Active viewVitamin A / retinol
01 / Vitamin A / retinol
Retinol enters tissue biology
Dietary vitamin A is transported and processed across tissue-specific pathways.
02 / Upstream ligand formation
ALDH enzymes generate ligands
ALDH1a enzymes participate in forming retinoid and rexinoid nuclear receptor ligands.
03 / Nuclear receptor signaling
Ligands activate RAR / RXR
Retinoic acid and rexinoid ligands activate nuclear receptor signaling and transcription.
04 / Multiple disease areas
Pathway activity shapes disease biology
Scientific evidence connects retinoid signaling with metabolism, immunity, cancer biology, and reproduction.
05 / Inhibition strategy
Kayothera targets the source
Kayothera is developing oral small molecules designed to inhibit ligand formation upstream.
01 / 05
Pipeline at a glance
One pathway strategy across three development programs
The stage visualization preserves the relative program progress shown on Kayothera’s original Science page. Stage descriptions are directional and should not be interpreted as new regulatory-status claims.
ProgramTarget IDIn VitroIn Vivo POCDDCIND-enablingINDPhase 1
KAYO-1732Type 2 diabetes / cardiometabolic diseaseDDC / approaching IND-enabling
Target ID
In Vitro
In Vivo POC
DDC
IND-enabling
IND
Phase 1
KAYO-2000ObesityIn Vivo POC
Target ID
In Vitro
In Vivo POC
DDC
IND-enabling
IND
Phase 1
KAYO-1609Male contraception / reproductive healthIND-enabling / toward IND
Target ID
In Vitro
In Vivo POC
DDC
IND-enabling
IND
Phase 1
Relative progress reflects Kayothera’s original Science-page pipeline chart and remains subject to client confirmation, study outcomes, regulatory feedback, funding, and company strategy.
Program science
A shared strategy, tuned to distinct biology
Each program applies the upstream inhibition strategy to a specific enzyme, tissue context, and development priority.
01KAYO-1732Type 2 diabetes / cardiometabolic disease
Pathway focus
Retinoid synthesis / ALDH1a3-related biology
KAYO-1732 is designed to inhibit retinoid synthesis in the pancreas, adipose tissue, and vasculature. Existing Kayothera research supports its potential to prevent or reverse type 2 diabetes by restoring pancreatic β-cell function and healthy metabolism.
Being developed as a potential disease-modifying therapy for type 2 diabetes and cardiovascular disease.
Scientific focus
ALDH1a3 biology, pancreatic β-cell function, adipose tissue, vasculature, and metabolic dysfunction.
02KAYO-2000Obesity
Pathway focus
Rexinoid pathway / ALDH1a1-related biology
KAYO-2000 targets a genetically validated obesity driver in the rexinoid pathway, which regulates thyroid and mitochondrial function.
Being developed as a next-generation oral weight-loss therapy designed to increase thyroid function and energy expenditure to support healthy weight loss.
Scientific focus
ALDH1a1 and rexinoid signaling, thyroid function, mitochondrial function, adipogenesis, and energy expenditure.
03KAYO-1609Male contraception / reproductive health
Pathway focus
ALDH1a2 / retinoic acid synthesis / Sertoli cells
KAYO-1609 is designed to block ALDH1a2 expressed in testicular Sertoli cells, thereby blocking retinoic acid synthesis.
Retinoic acid synthesis is necessary for spermatogonia differentiation and spermiation, supporting the scientific rationale for male contraceptive development.
Scientific focus
ALDH1a2, testicular Sertoli cells, retinoic acid synthesis, spermatogonia differentiation, and spermiation.
Featured scientific proof
A peer-reviewed foundation for pathway inhibition
JEMJournal of Experimental Medicine
Peer reviewed2024 / Review
Featured peer-reviewed foundation
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
A major review connecting retinoid nuclear receptor signaling to cancer biology, metabolic dysfunction, diabetes, obesity, and emerging therapeutic inhibition strategies.
Read the publicationScientific references
Publications
Selected publications supporting the scientific rationale across retinoid signaling, metabolic biology, and pathway inhibition.
01
iScience, Volume 28, Issue 11, 113675
Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3
Foundational research on targeting ALDH1A3 to develop antagonists of the retinoid nuclear receptor pathway.
02
Journal of Experimental Medicine
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
A review connecting retinoid nuclear receptor signaling with cancer biology and metabolic syndromes.
03
Nature Communications
Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure
Research supporting the scientific rationale for ALDH1A3 inhibition in pancreatic β-cell biology.
04
Nature Cancer
Emerging strategies for treating metastasis
A broader scientific reference on emerging approaches to metastatic disease biology.
05
Experimental & Molecular Medicine
Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes
A review of β-cell dedifferentiation and its relevance to type 2 diabetes treatment strategies.
Scientific inquiries
Connect with Kayothera’s scientific team
Explore how the upstream pathway strategy connects with Kayothera’s development programs.